Bremelanotide (PT-141) Demonstrates Erectogenic and Pro-Sexual Effects in Phase II Trials

Male and female sexual dysfunction represent major unmet clinical needs. Current standard-of-care for erectile dysfunction relies on phosphodiesterase-5 (PDE5) inhibitors, which carry a risk of hypotension and act peripherally rather than centrally. The discovery that systemic administration of the synthetic alpha-MSH analog MT-II reliably induced penile erections across multiple species — including humans — opened a new mechanistic avenue: targeting melanocortin receptors in the central nervous system, particularly the hypothalamus, to modulate sexual response. Female sexual dysfunction, for which no well-established pharmacotherapy exists, has remained especially underserved, making centrally acting agents with dual-sex applicability highly relevant.

Bremelanotide (PT-141), a synthetic cyclic peptide derived from MT-II and administered intranasally, was evaluated in Phase II clinical trials in both male and female participants for sexual dysfunction endpoints. Preclinical work in female rats examined pre-copulatory behaviors as proxies for sexual arousal. Alongside bremelanotide, other melanocortinergic agents — HP-228, THIQ, and MT-II — were reviewed for erectogenic properties. The primary endpoints included measures of erection frequency and quality in males and sexual desire and arousal in females. This paper is a review synthesizing clinical trial data, animal model findings, and proposed CNS mechanisms of action.

Phase II clinical trial data for bremelanotide supported efficacy for erectile dysfunction, with results consistent across the reviewed male study populations. Preclinical animal studies demonstrated that melanocortin agonists evoked pre-copulatory behaviors in female rats analogous to sexual arousal, and preliminary clinical data extended these findings to increased sexual desire and arousal in women. Several agents — MT-II, HP-228, THIQ, and bremelanotide — were each found to have erectogenic properties attributable to binding at melanocortin receptors in the CNS, with the hypothalamus identified as a particularly important site. Importantly, bremelanotide was well tolerated across clinical experience and was not associated with the hypotension observed with PDE5 inhibitors, representing a meaningful safety differentiation.

Bremelanotide is the only melanocortinergic agent clinically studied in both males and females, and Phase II data validate melanocortin-based therapy for erectile dysfunction while preliminary data support a role in female sexual dysfunction.

Written by TitrateLab, separately from the study summarized above.